The estimated Net Worth of Ronald J Prentki is at least $170 Tysiąc dollars as of 4 February 2005. Ronald Prentki owns over 26,000 units of Progenics Pharmaceuticals stock worth over $170,470 and over the last 21 years Ronald sold PGNX stock worth over $0.
Ronald has made over 11 trades of the Progenics Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Ronald exercised 26,000 units of PGNX stock worth $240,500 on 4 February 2005.
The largest trade Ronald's ever made was exercising 26,000 units of Progenics Pharmaceuticals stock on 4 February 2005 worth over $240,500. On average, Ronald trades about 7,418 units every 17 days since 2003. As of 4 February 2005 Ronald still owns at least 41,578 units of Progenics Pharmaceuticals stock.
You can see the complete history of Ronald Prentki stock trades at the bottom of the page.
Ronald's mailing address filed with the SEC is 4 CHARTER OAK LANE, , GREENWICH, CT, 06830.
Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch oraz Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
Progenics Pharmaceuticals executives and other stock owners filed with the SEC include: